Medium Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency
(metabolic condition: fatty acid oxidation disorder)

Also known as:
- medium-chain acyl-coenzyme A dehydrogenase deficiency
- ACADM deficiency

What are fatty acid oxidation disorders?
Fatty acid oxidation disorders (FAOD) are a group of inherited conditions in which fatty acids cannot be broken down to provide the body with energy. Fatty acids are a key source of energy during fasting or stress, such as during an illness. An inability to metabolize fatty acids leads to an accumulation of toxic metabolites in the body along with cellular energy deficiency which in combination can cause serious health problems.

What is MCAD deficiency?
Medium chain acyl-CoA dehydrogenase (MCAD) is one of the mitochondrial enzymes required in the breakdown of fatty acids to produce energy. MCAD breaks down fatty acids between 6 and 12 carbon atoms in length. People with MCAD deficiency are unable to break down these medium chain fatty acids to produce energy.

What causes MCAD deficiency?
MCAD deficiency results from mutations in the MCAD gene resulting in absent or decreased activity of the enzyme.

How common is MCAD deficiency?
The incidence of MCAD deficiency is about 1 in every 12,000 infants born in Canada.

What are the clinical features of MCAD deficiency?
Although children with MCAD deficiency may appear normal at birth, during a period of fasting (such as during an illness), a child who was previously healthy may present with lethargy, vomiting, hypoketotic hypoglycemia and seizures. While the first episode usually presents between 2 months and 2 years of age, it is possible that clinical features may present at any age. Coma and death may occur if treatment is not initiated quickly. These children may also have an enlarged liver and acute liver disease.

What is the screening test for MCAD deficiency?
A specific pattern of fatty acid metabolites is detected on the newborn blood spot screen. Newborn blood spot screening is not 100% perfect. Infants with clinical symptoms need timely assessment and diagnostic testing even if their screen result is normal.

How is the diagnosis confirmed?
The diagnosis of MCAD deficiency is confirmed by detecting specific metabolites in urine or on blood acylcarnitine analysis. Further testing may include enzyme analysis and/or mutation analysis of the MCAD gene. Specialists at the clinics listed below will arrange diagnostic testing.

How is MCAD deficiency treated?
MCAD deficiency is effectively treated by avoidance of fasting. A low fat diet and carnitine supplementation may be considered. Parent education is an important component of treatment, including advising parents on actions to be taken when their child develops a minor illness. Prompt treatment of a metabolic crisis with intravenous fluids and glucose is necessary. The treatment is lifelong.

What is the outcome of treatment for MCAD deficiency?
Without treatment, 25% of patients die during the first metabolic crisis and of the survivors, 50% have neurological impairment or developmental delay. Prevention of fasting and prompt treatment of metabolic crises is effective in preventing long-term consequences of MCAD deficiency.

Is MCAD deficiency inherited?
MCAD deficiency is inherited as an autosomal recessive trait. Parents of a child with MCAD deficiency are carriers of the condition and have a 1 in 4 chance of having another affected child in each subsequent pregnancy. MCAD deficiency carriers are healthy. Genetic counselling and prenatal testing is available to all families with MCAD deficiency.

For additional resources, please call:
Edmonton Medical Genetics Clinic
8-53 Medical Sciences Building
8440-112 St. N.W.
Edmonton, AB T6G 2H7
Phone: 780-407-7333
Fax: 780-407-6845
Emergency consultations:
Phone 780-407-8822 and ask for the genetic metabolic specialist on call.

Inherited Metabolic Disorders Clinic
Alberta Children’s Hospital
2888 Shaganappi Trail N.W.
Calgary, AB T3B 6A8
Phone: 403-955-7587
Fax: 403-955-3091
Emergency consultations:
Phone 403-955-7211 and ask for the specialist on call for metabolic diseases.

Early screening, detection and treatment – every infant, every time
For more information about the NMS Program, visit www.albertahealthservices.ca/newbornscreening.asp
APRIL 2013 NMS Program Conditions MCAD V1